Expert: Half-life extended bispecific T-cell engager targeting STEAP1 (six-transmembrane epithelial antigen of the prostate 1) and CD3 on T cells.

Everyday: Connects T-cells to prostate cancer cells via STEAP1, a protein found on prostate tumors. Forces the immune system to attack prostate cancer that has spread.

Targets: ["STEAP1"]

First-in-class STEAP1 BiTE for mCRPC. Phase 1 showed ~30% PSA50 response in heavily pretreated patients. Two Phase 3 studies: XALute (post-taxane) and XALience (chemo-naive w/ abiraterone). STEAP1 expressed on ~90% of prostate cancers.